Cargando…

Comparison of Cardiovascular Medicines Prices in Four European Countries

The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-dose combinations (FDCs) in four countries us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitkova, Zornitsa, Vasileva, Mariya, Savova, Alexandra, Manova, Manoela, Terezova, Silvia, Petrova, Guenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472524/ https://www.ncbi.nlm.nih.gov/pubmed/32974262 http://dx.doi.org/10.3389/fpubh.2020.00433

Ejemplares similares

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
por: Tkachova, Oksana, et al.
Publicado: (2019)

Analysis of the Household and Health Care System Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
por: Karanyotova, Stephanie, et al.
Publicado: (2023)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
por: Pisana, Alice, et al.
Publicado: (2022)

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
por: Zemplényi, Antal, et al.
Publicado: (2023)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Pharmacy network and access to medicines in selected eastern European countries: comparative analysis
por: Lakić, Dragana, et al.
Publicado: (2012)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Prices of oncology medicines in European countries, Australia and New Zealand
por: Vogler, Sabine, et al.
Publicado: (2015)

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
por: Dane, Aniek, et al.
Publicado: (2023)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Evaluation of the Strategies to Control COVID-19 Pandemic in Four European Countries
por: Gianino, Maria Michela, et al.
Publicado: (2021)

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries
por: Dimitrova, Maria, et al.
Publicado: (2020)

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature
por: Ocran Mattila, Phyllis, et al.
Publicado: (2021)

Gender-specific social and environmental correlates of active travel to school in four European countries: the HBSC Study
por: Brindley, Catherina, et al.
Publicado: (2023)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fs56tfdnt6ang0ust2o69nbg6c